Article

Square-edge design of lens effective against PCO

Washington, DC—The three-piece square-edge design of the Tecnis IOL platform (AMO) seems to protect the eye against development of posterior capsular opacification (PCO) by preventing migration of epithelial cells for at least 3 years after implantation, reported Michael Colvard, MD, FACS, at the annual meeting of the American Society of Cataract and Refractive Surgery.

Washington, DC-The three-piece square-edge design of the Tecnis IOL platform (AMO) seems to protect the eye against development of posterior capsular opacification (PCO) by preventing migration of epithelial cells for at least 3 years after implantation, reported Michael Colvard, MD, FACS, at the annual meeting of the American Society of Cataract and Refractive Surgery.

The Tecnis Edge is a continuous 360° square-edge configuration that has a "barrier effect," uninterrupted by haptic insertion.

In the cases under discussion, Dr. Colvard pointed out that he attempted to make all the anterior capsulotomies central in location and 4 mm in diameter and he used bimanual irrigation/aspiration for cortical cleanup. All the posterior capsules were polished, and the anterior capsules were not.

In this study, 29 patients had the Tecnis three-piece silicone IOL platform implanted between August and December 2001. Dr. Colvard and colleagues conducted a retrospective review of the rates of YAG capsulotomy in patients who had a minimal follow-up of 3 years. A prospective evaluation of the PCO was done using slit-lamp examination and digital retroillumination photography, using the EPCO 2000 analysis system.

Capsular changes demonstrated on retroillumination photos are graded on a scale from 0 to 4 as follows: 0, crystal clear; 1 (minimal), mild wrinkling of the capsule, mild homogeneous layers or sheets of lens epithelium cells; 2 (mild), honeycomb patterns of PCO, thicker homogeneous layers, denser fibrosis; 3 (moderate), classical Elschnig pearls, very thick homogeneous layer; and 4 (severe), very thick Elschnig pearls with a "darkening effect," any type of severe opacification.

No YAG capsulotomies Three-year clinical data were obtained for the 29 patients. Of these, 23 patients were examined 3 years after implantation at the Colvard Eye Center, and six patients, who were not available for examination, were interviewed by telephone. None of the patients had required a YAG posterior capsulotomy.

"To maintain consistency with previous publications, we looked at PCO values for the entire optic and the central 3-mm zone. The averaged PCO values demonstrated virtually no capsular opacification over the area of the entire optic or none whatsoever of the central 3-mm zone," Dr. Colvard explained.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
© 2025 MJH Life Sciences

All rights reserved.